Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (2166)	11/30/2000 1:20:05 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 52153

George: Don't know much. To my knowledge, the antigen was described by Koprowski's lab years before Ingene ever worked with it. It's at least 15 years out from an initial description, and it's expressed on normal epithelium. That's the downside. I wait for data to point at the upside. No bias. What does Steve Carroll say, when you get him away from Scannon and ask for the truth? Steve is very good, and he's honest. >> My point was that part of the past research expenses have been transformed into a partnership package with BAX. << Your point is clear, and it was clear the first time. There are now over 60 million shares out. The research premium isn't zero. Dellio et al. can put product in bottle as well as anyone. Genentech made a wise choice.